Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Alchemab Therapeutics wins Best Start-up Biotech Company at the OBN Awards 2020

Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.

BioEscalator Pitch Battle 2021

PepGen wins the BioEscalator Pitch Battle 2021 with an excellent pitch on how the company is harnessing the power of its Enhanced Delivery Peptide technology to solve the drug-delivery challenge and realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases.

MoA Technology Graduates from The BioEscalator

MoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.

HRH The Earl of Wessex visits Oxfordshire virtually

HRH The Earl of Wessex speaks with Oxfordshire entrepreneurs, including Atherton Mutombwera, CEO of Hutano Diagnostics.

MoA Technology secures further funding

MoA Technology, a spin-out company from Oxford University’s Department of Plant Sciences, has secured an additional £5M funding for its series A round to support the expansion and acceleration of its discovery programme.

Alchemab raises £60M Series A funding

The biotech company, which joined the BioEscalator Innovation Lab as a new start-up in December 2019, secures Series A funding to advance its novel platform for identifying disease-modifying antibody therapeutics.

Virginia Corless joins MoA Technology as CEO

MoA Technology has a new CEO, Dr Virginia Corless, an experienced leader of cutting-edge enterprises that aim to make agriculture more efficient and sustainable.

MediMabBio raises $18M Series A funding

BioEscalator biotech, MediMab Biotherapeutics, secures Series A funding to advance two immuno-oncology candidate therapeutics in pre-clinical studies.

PepGen Announces Formation of Scientific Advisory Board

PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the peptide-mediated delivery of nucleic acid therapeutics, has announced the formation of its Scientific Advisory Board.

PepGen appoints James McArthur as President and CEO

BioEscalator resident biotech PepGen, has announced the appointment of serial entrepreneur Dr James McArthur as President and Chief Executive Officer (CEO). The McGill alumnus brings a wealth of experience in guiding early and clinical-stage healthcare ventures, including Vtesse and Tiburio Therapeutics.

Strategic collaboration announced between Enara Bio and Boehringer Ingelheim

The partnership deal, worth over €876M, will enable Enara Bio to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.

Theolytics raises $6.8M to advance oncolytic viral therapy against cancer

Theolytics Series A funding round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI).

Enara Bio adds further world-class cell therapy and immuno-oncology expertise to senior leadership team and Scientific Advisory Board

These appointments will provide experienced industry leadership and perspective to support Enara Bio's rapid growth and development in key strategic areas.

PepGen secures Series A funding

RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases.

Enara Bio moves to The Oxford Science Park

Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies.

UK BIA Antibody Taskforce reaches major milestone against COVID-19

The UK Antibody Taskforce, led by Alchemab’s CSO, Dr Jane Osbourn OBE, has identified antibody combinations for a potential therapeutic antibody cocktail to treat COVID-19.

Base Genomics acquired by Exact Sciences for $410M

The OSI backed venture and BioEscalator resident, Base Genomics has been acquired by the US based molecular diagnostics company, Exact Sciences for $410M.

Alchemab announced as finalists for OBN Awards 2020

Novel therapeutics company, Alchemab Therapeutics, has been shortlisted in the Best Start-Up category of the 12th Annual OBN Awards.

Alchemab collaborates with leading AI institute to advance drug discovery

BioEscalator residents Alchemab Therapeutics has announced a partnership with the Alberta Machine Intelligence Institute (Amii), a global leader in machine intelligence.

Load More